转移性 BCC (mBCC) 很少见，有关患者和肿瘤危险因素、最佳治疗和疾病预后的数据有限。旨在评估按转移部位分层的 mBCC 患者和肿瘤特征、治疗方法和结果。对 50 名患者进行的回顾性队列研究-三名转移性基底细胞癌患者在马萨诸塞州波士顿的四个大型学术中心接受治疗；宾夕法尼亚州费城； 2005 年 1 月 1 日至 2021 年 12 月 31 日期间，在俄亥俄州克利夫兰市和俄亥俄州克利夫兰进行了研究。4 个中心共鉴定出 53 名 mBCC 患者，其中 22 名（42%）名转移性 BCC 仅限于淋巴结扩散，31 名（58%）名患者患有转移性 BCC伴有远处器官扩散（有或没有淋巴结受累）。总体而言，一半 (n=11) 的淋巴结转移患者达到了疾病完全缓解，而只有 1 (3%) 的远处转移患者达到了疾病完全缓解。淋巴结和远处转移患者的 5 年生存率分别为 89.3% 和 61.0%。 由于疾病罕见，样本量较小 结论和相关性：淋巴结疾病患者更有可能获得疾病缓解，而远处转移患者更有可能获得疾病缓解患有持续性疾病并死于疾病。然而，即使是 IV 期疾病，5 年生存率也超过 50%。版权所有 © 2023。由 Elsevier Inc. 出版。

Metastatic BCC (mBCC) is rare and there are limited data regarding patient and tumor risk factors, optimal treatments, and disease prognosis.To assess patient and tumor characteristics, therapeutics, and outcomes of mBCC stratified by location of metastasis.Retrospective cohort study of fifty-three patients with mBCC treated at four large academic centers in Boston, Massachusetts; Philadelphia, Pennsylvania; and Cleveland, Ohio between January 1, 2005 to December 31, 2021.A total of 53 patients with mBCC were identified across 4 centers, 22 (42%) of whom had mBCC with spread limited to lymph nodes and 31 (58%) patients with distant organ spread (with or without lymph node involvement). Overall, half (n=11) of patients with nodal metastasis achieved complete remission of disease, compared to just 1 (3%) patient with distant metastasis. The 5-year survival for nodal and distant metastatic patients was 89.3% and 61.0%, respectively.Small sample size due to disease rarity CONCLUSIONS AND RELEVANCE: Patients with nodal disease are more likely to have disease remission whereas patients with distant metastasis are more likely to have persistent disease and die from their disease. However, 5-year survival rates exceed 50%, even for stage IV disease.Copyright © 2023. Published by Elsevier Inc.